Eupraxia Pharmaceuticals: Durable EP-104GI Data and Upcoming Catalysts Support Buy Rating

Bloom Burton analyst David Martin PhD maintained a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $14.00.

David Martin PhD has given his Buy rating due to a combination of factors tied to Eupraxia Pharmaceuticals’ advancing clinical program. The most recent update from the RESOLVE phase 1b/2a trial in eosinophilic esophagitis showed that additional patients followed out to 52 weeks after a single EP-104GI dose continued to demonstrate meaningful clinical benefit and tissue-level improvement, in line with earlier interim observations.

These expanded data increase his conviction that EP-104GI can support durable, once-yearly dosing, which he views as a key competitive and commercial advantage if confirmed in larger studies. He also notes that results from higher-dose cohorts are still pending, creating further potential upside if they enhance efficacy without compromising safety, and this combination of consistent long-term data and future catalysts underpins his positive view on the stock.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.